With limited early detection methods and poor prognosis, pancreatic cancer is one of the most aggressive and challenging malignancies to treat. This is where OncoSil Medical Limited (ASX: OSL) steps in. As a leader in medical technology, the company has developed the OncoSil device, a groundbreaking brachytherapy solution designed to transform pancreatic cancer treatment. By delivering beta radiation directly to the tumour, the OncoSil device offers renewed hope to patients and healthcare providers alike.
Recently, OncoSil Medical has made significant strides in broadening access to its innovative technology. New distribution agreements with leading medical distributors across Europe, the Middle East, and Africa mark the company’s entry into previously underserved markets. These partnerships signify not only a new chapter for OncoSil Medical but also a beacon of hope for patients in these regions.
Transforming Care in the Nordics and Egypt
OncoSil Medical’s recent agreements with CardiRad for the Nordics and Femto Trade for Egypt highlight its global ambitions.
Bringing Innovation to the Nordics
CardiRad, a leading distributor of cutting-edge medical technologies, will introduce the OncoSil device to Sweden, Denmark, Norway, and Finland. With its expertise in oncology and nuclear medicine, CardiRad is well-positioned to bring this transformative solution to Nordic patients. The partnership underscores OncoSil Medical’s commitment to improving access to advanced treatments in regions where the demand for innovative oncology solutions continues to grow.
Expanding Access in Egypt
Femto Trade, a premier distributor specialising in nuclear medicine and interventional oncology, will spearhead the introduction of the OncoSil device in Egypt. Leveraging its deep market knowledge and established relationships with top medical institutions, Femto Trade will play a crucial role in delivering this life-changing technology to Egyptian patients battling locally advanced unresectable pancreatic cancer.
Nigel Lange, CEO and Managing Director of OncoSil Medical, emphasised the importance of these partnerships:
“Our agreements with CardiRad and Femto Trade reflect OncoSil’s dedication to expanding access to our innovative brachytherapy treatment on a global scale. These partnerships mark an important step in our mission to provide life-changing care solutions to patients worldwide.”
Strengthening Footprints in the Middle East
OncoSil Medical’s collaboration with Al Zahrawi Medical Supplies LLC marks another pivotal milestone in its journey. Based in Dubai, Al Zahrawi Medical Supplies is a leading distributor across the Gulf Cooperation Council (GCC) countries, including the UAE, Qatar, Oman, and Bahrain.
Meeting Growing Regional Demand
The Middle East faces a rising prevalence of pancreatic cancer, creating an urgent need for advanced treatment options. Through its partnership with Al Zahrawi, OncoSil Medical is addressing this demand head-on. The distributor’s proven track record and extensive network ensure that the OncoSil device will reach patients who need it most.
Nigel Lange expressed his optimism for this venture:
“We are thrilled to partner with Al Zahrawi Medical Supplies, a highly respected distributor with a proven track record across the GCC region. This agreement marks an important step in expanding access to our innovative OncoSil™ product in the Middle East, where there is a growing demand for effective treatments for pancreatic cancer.”
A Device That Redefines Pancreatic Cancer Treatment
The OncoSil device is a CE-marked brachytherapy solution designed to deliver beta radiation directly into a tumor. By bypassing surrounding healthy tissues, it minimises side effects while enhancing therapeutic outcomes. This precision treatment not only complements existing therapies but also opens doors to new possibilities in cancer care.
The Road Ahead: Expanding Horizons
These recent partnerships reflect OncoSil Medical’s unwavering commitment to transforming cancer treatment on a global scale. By strategically entering markets in the Nordics, Egypt, and the GCC region, the company is ensuring that more patients can benefit from its groundbreaking technology.
As OncoSil Medical continues to push boundaries, it sets a powerful example of innovation and determination in the fight against one of the world’s deadliest cancers. With each step into new territories, the company is not just expanding its global presence—it’s creating a brighter future for patients worldwide.
